[Effect of benidipine on plasma level of calcitonin gene-related peptide in essential hypertension].
To explore the effect of benidipine, a calcium channel blocker on the plasma levels of calcitonin gene-related peptide (CGRP) in patients with essential hypertension. 58 outpatients with essential hypertension were treated with benidipine 4-8 mg/day for 8 weeks. 38 matched healthy people were taken as controls. The plasma levels of CGRP were measured in all patients before and after treatment and in controls. The plasma levels of CGRP in hypertensive patients were significantly lower than those in controls (minimal value: 1.28 vs 39.95 ng/L; maximal value: 43.72 vs 155.59 ng/L; P <0.001). In hypertensive patients, treatment with benidipine for 2 weeks markedly decreased systolic pressure and diastolic pressure and its depressor effect was maintained during the study (P <0.05). At 8 week after treatment, the plasma levels of CGRP in hypertensive patients were significantly increased compared with those before treatment (minimal value: 2.84 vs 1.28 ng/L; maximal value: 123.99 vs 43.72 ng/L; P <0.001). Benidipine, a calcium channel blocker significantly decreases blood pressure concomitantly with an increase in the plasma levels of CGRP in the patients with essential hypertension.